Zhang Zhang C C Wu Wu Z Z Li Li J-W J-W Zhao Zhao H H Wang Wang G-Q G-Q The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality Int J Antimicrob Agents Int J Antimicrob Agents 2020 2020 10.1016/j.ijantimicag.2020.105954 10.1016/j.ijantimicag.2020.105954. Here, IL6R is linked to congenital rubella syndrome.